Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Also known as: CHIA TAI TIANQING | CHIATAI TIANQING PHARMACEUTICAL Co.,Ltd | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | Cttq | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd | Nanjing Chia-tai Tianqing Pharmaceutical | Zhengda Tianqing Pharmaceutical Group Co., Ltd.
Highest phase reached
Phase 4
Timeline
1960s
- Jun 1, 1969
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd— Founded
2020s
- Feb 7, 2020
fulvestrant— Marketing Organization
Drugs by trial phase (217 distinct, 427 trials)
Phase 4 (24 own, 0 via acquisition)
Phase 3 (64 own, 0 via acquisition)
Phase 2 (67 own, 0 via acquisition)
Phase 1 (59 own, 0 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Agranulocytosis
- Asthma
- Bone Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Chemical and Drug Induced Liver Injury
- Cholangiocarcinoma
- Colonic Diseases
- Colorectal Neoplasms
- Constipation
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Digestive System Diseases
- Digestive System Neoplasms
- Endometrial Neoplasms
- Esophageal Squamous Cell Carcinoma
- Fibrosis
- Gastrointestinal Diseases
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Healthcare-Associated Pneumonia
- Hematologic Neoplasms
- Hemophilia A
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Herpes Zoster
- Hodgkin Disease
- Idiopathic Pulmonary Fibrosis
- Inflammation
- Intestinal Diseases
- Intestinal Neoplasms
- Kidney Neoplasms
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Lung Diseases, Obstructive
- Lung Neoplasms
- Lymphohistiocytosis, Hemophagocytic
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Multiple Myeloma
- Mycoses
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Nasopharyngeal Carcinoma
- Nausea
- Neoplasms
- Neoplasms by Site
- Neuroendocrine Tumors
- Osteoporosis
- Osteoporosis, Postmenopausal
- Pancreatic Neoplasms
- Pneumonia
- Pneumonia, Bacterial
- Preleukemia
- Prostatic Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Fibrosis
- Rectal Diseases
- Recurrence
- Sarcoma
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Syndrome
- Thyroid Diseases
- Thyroid Neoplasms
- Triple Negative Breast Neoplasms
- Urologic Neoplasms
- Uterine Cervical Neoplasms
- Vomiting
- Wounds and Injuries
Marketed drugs (4)
Recent trials (50)
- NCT07177872Lead sponsorPhase 3Jun 30, 2026
- NCT07269145Lead sponsorPhase 1Dec 31, 2025
- NCT07291050Lead sponsorPhase 1Dec 31, 2025
- NCT07294261CollaboratorPhase 2Dec 23, 2025
- NCT07177859Lead sponsorPhase 3Nov 30, 2025
- NCT07252908Lead sponsorPhase 2Nov 30, 2025
- NCT07267130Lead sponsorPhase 1Nov 25, 2025
- NCT07179679Lead sponsorPhase 1Oct 31, 2025
- NCT07156643CollaboratorPhase 2Oct 1, 2025
- NCT07172126Lead sponsorPhase 1/Phase 2Sep 30, 2025
- NCT07147946Lead sponsorPhase 3Sep 30, 2025
- NCT07043725Lead sponsorPhase 3Sep 15, 2025
- NCT07083739Lead sponsorPhase 2Aug 31, 2025
- NCT07113925Lead sponsorPhase 1Aug 1, 2025
- NCT07052097Lead sponsorPhase 2Jul 31, 2025
Details
- Founded
- Lianyungang, CN Jun 1, 1969
- Last known activity
- Jun 30, 2026
Notes
--- Notes from CTTQ: --- Notes from Nanjing Chia-tai Tianqing Pharmaceutical: https://www.cttq.com/en/ --- ---